Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer. - Bendell JC; Ervin TJ; Gallinson D; Singh J; Wallace JA; Saleh MN; Vallone M; Phan SC; Hack SP (Clinical colorectal cancer, 2013)